Related Experiment Video
Updated: Mar 31, 2026

07:51
Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
Published on: March 20, 2026
129
Using B-cell-targeting drugs to achieve marked efficacy in anti-signal recognition particle myopathy: two case
Zhuoyao Song1,2,3, Jiaxun Zhong1, Hongxu Cui1
1Department of Rheumatology and Immunology, Neijiang First People´s Hospital, Neijiang, Sichuan, China.
Immunologic Research
|March 29, 2026
Abstract
No abstract available in PubMed .
Keywords:
Anti-signal recognition particle (anti-SRP) myopathyB‑cell–targeted therapyLow doseRituximab (RTX)Telitacicept (RC-18)More Related Videos
Related Concept Videos
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
749
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
749
Myasthenia Gravis: Overview and Treatment
3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K

